BioChain provides methylated and low-methylated DNA matched pairs that may be used as positive and negative controls for DNA methylation studies. They are a useful tool for analyzing the efficiency of bisulfite conversion, which is a key technique used in methylated DNA sequencing.
DNA methylation is an epigenetic modification that does not change the existing nucleotide sequence, and yet it may have a profound role in the early stages of cancer development. Changes in DNA methylation are used as a method of gene regulation, and abnormal methylation patterns may result in inappropriate silencing of tumor suppressors. Therefore, further elucidation of DNA methylation pathways will be important for early diagnosis of cancer.
BioChain’s tissue genomic DNAs are isolated from a wide variety of tissues using a proprietary modified guanidine thiocyanate technique. The quality and purity of genomic DNA are tested by spectrophotometer and electrophoresis. A260/280 is between 1.8 and 2.0, and A260/230 is >2.0 (detected in 10 mM Tris-Cl, pH 7.5). Contamination of RNA, polysaccharides and proteoglycans has been effectively eliminated.